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Graft failure is a highly unsatisfactory outcome of allo-
geneic transplant. Several factors have been identiﬁed which
may predict for graft failure, however factors inﬂuencing the
success of a second allogeneic transplant in this setting are
not well studied.
Methods: The BSBMT analysed 130 patients receiving
a second allogeneic transplant for graft failure. Patients were
identiﬁed from the BSBMT Data Registry and transplant
centres were approached to provide follow up data.
Results: The median age of patients was 9 (range 4m-69),
with 53 (40%) being adults (>18). The disease was malignant
(47%) or non-malignant (53%). The majority of patients had
conditioning for the second transplant (68%), which included
serotherapy (Alemtuzumab/ATG) in almost all cases. This
was myeloablative (30%) or reduced intensity (39%)
(compared to 56% and 43%, respectively, at ﬁrst transplant).
The donor was a sibling (24%), unrelated donor (58%) or
other relative (18%). In 74% the same donor was used. The
stem cell source was bone marrow (41%), PBSC (54%), both
(2%) and UCB (3%) (compared to 53%, 38%, 1% and 7%,
respectively, at ﬁrst transplant). Stable engraftment occurred
in 88% of patients following the second transplant. Factors
associated with a signiﬁcant increase in engraftment failure
were older age (p¼0.003), male recipients (p¼0.025),
reduced intensity conditioning (compared to myeloablative
or none) (p¼0.031), the use of a different donor (p¼0.026)
and transplant for a malignant diagnosis (p¼0.005). Age
(HR¼11.52, p¼0.001) and the use of a different donor
(HR¼8.17, p¼0.003) remained signiﬁcant in the multivariate
analysis. The donor type, stem cell source and the time post
ﬁrst transplant did not impact on engraftment. Overall
survival was 60% at 5 years in the entire group. OS was
signiﬁcantly worse in adult patients (37% vs 74%, p<0.0001),
those with malignant disease (40% vs 78%, p¼0.0001) and
those transplanted beyond 3months after the ﬁrst transplant
(47% vs 65%, p¼0.02). No other factors tested were signiﬁ-
cant, and only malignancy remained signiﬁcantly associated
with OS in multivariate analysis (HR¼2.53, p¼0.018).
Conclusion: These encouraging results suggest that
successful engraftment and long term survival is possible
following a second transplant for graft failure. Although
outcomes are superior in children and those with non-
malignant disease, over a third of adult patients and those
with malignant diseases can also achieve long term survival.25
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The conﬁrmatory typing (CT) stage of unrelated donor
acquisition is a key source of delays to haematopoietic cell
provision. Identifying factors that might predict donor
deferral at this stage is important in reducing this delay and
improving patient outcome.
Methods: All CT requests made from Anthony Nolan
between 2010-11 were reviewed, and reason for deferral and
donor characteristics documented. Associations were deter-
mined using multivariate logistic regression analysis.Results: Of 7542 requests, 56.3% were completed, 38.2%
cancelled for donor reasons and 5.5% cancelled for transplant
centre reasons. Of donor cancellations 19.4% were personal,
34.1% medical, 36% no contact made, 7.9% overseas/
emigrated and 2.6% other. When compared to UK/North
European donors, African (OR 2.56, p¼0.001), Afro-Carib-
bean (OR 2.13, p<0.001), Asian (OR 2.45, p<0.001) and
Mediterranean donors (OR 1.93, p¼0.005) were more likely
to defer for donor reasons. Female donors were more likely
to defer for donor reasons (OR 1.19, p¼0.001), even when
pregnancy was excluded. This may be partly explained by
more medical deferrals (54% vs 46%). Donor age was also
associated with deferral, with more deferred aged 31-45 (OR
1.20, p¼0.002) and 46-60 (OR 1.43, p<0.001), compared to
18-30. This difference is largely explained by higher rates of
medical deferral (20.9% vs 34.6% vs 45.8% of all donor
cancellations for donors aged 18-30, 31-45 and 46-60
respectively), despite older donors being more easily con-
tacted, with fewer personal deferrals. Of medical deferrals,
19.4% of donors were deferred for morbid obesity (BMI>35),
14.4% for malignancy, 11.1% autoimmune conditions, 10.6%
cardiac, 5.3% back complaints and 7.1% diabetes. Blood
donors were less likely to be deferred for donor reasons (OR
0.72, p<0.001).
Conclusion: Despite over 20 million unrelated donors listed
on registers worldwide, high rates of donor attrition
considerably attenuate this resource and have a signiﬁcant
impact on donor provision. Donors from some ethnic
minorities have a particularly high rate of attrition. As
a registry, we are employing a number of strategies to
address the results of this study: increasing the base of
younger donors by reducing the joining age to 16-30, donor
pre-activation, use of social media to maintain contact with
donors and in depth interviews with those donors who
choose not to proceed.26
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Background: Allogeneic transplantation of haemopoietic
stem cells (HCT) from an HLA-matched related (MRD) or
unrelated donor (MUD) is a curative option for patients (pts)
affected by high-risk hematological diseases (HRHD). The
trend of growth of HCTs in adult pts with HRHD can be ex-
pected to continue based on acceptance and availability of
alternative donor. Few data are available for: i) the reliable
estimates of the number of HCT and the total number of pts
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donor sources.
A risk-adapted treatment strategy is crucial to improve
the outcome of pts with HRHD. Our policy is to offer a hap-
loidentical HCT to adult pts lacking a matched donor in the
appropriate time according to clinical indications
(www.leukemianet.org, www.ebmt.org). This policy is inte-
grated in ongoing protocols for primary disease.
Methods: Here we are reporting the intention-to-treat
(ITT) analysis of HCT in all consecutive HRHD pts
referred to our Institution between January 2004 and
June 2012.
Results: Indication to HCT was given to 611 pts (median age
49 y, range 10-76; male 394), 120 pts (20%) received
a transplant from a MRD; 187 pts (30%) activated a MUD
search; 118 pts (19% of total pts, 63% of MUD searching)
received a MUD transplant; 12 pts (2%) received a umbilical
cord blood unit. Overall, 237 pts received a haplo-HCT (49%).
The median time from indication to HCT was 87 days. The
median time from indication to activation was 12 days and
the median time from activation to HCT was 114 days (range
22-824). Lack of donor was not a limiting factor. Age was not
a limiting variable to HCT execution: 107 patients (out of 487
SCT e 22%) were in the 60-69 range of age. The overall
survival (OS) analysis in ITT for the entire populationwas 43%
at 2 years, with a median time of survival of 767 days. The
2yOS in pts transplanted in CRwas 60%, in pts transplanted in
PD is 25% (p <0.001).
The OS according to donor source (MRD vs MUD vs
haplo-HCT) was comparable (p¼ns) in pts transplanted in
CR.
The 2-year OS in pts affected by acute myeloid leukemia
was 66%, 60% and 13% for patients transplanted in CR1, >CR1
and PD, respectively. The outcome analysis (OS, relapse
incidence, transplant related mortality) per donor source
was comparable (p¼ns) within CR setting.
Conclusion: For many pts with HRHD, HCT from a MRD
provides the best chance for long-term survival. However,
only approximately 30% of individuals have a MRD. In our
experience, haplo-HCT offers a concrete option of cure to
HRHD pts: outcome results are superimposable to MRD
and MUD in pts in CR at HCT. In ITT analysis, 80% of
candidate pts received an HCT as a potential immuno-
therapy. All patients affected by HRHD, for whom an HCT
is part of their therapeutic program, should proceed with
a well-timed HCT whatever the stem cell source, and in
the absence of a fully HLA-compatible donor the option of
a haploidentical donor should be simultaneously consid-
ered.27
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Introduction: Reduced intensity conditioning (RIC) alloge-
neic hematopoietic cell transplantation (HCT) with alemtu-
zumab, ﬂudarabine, and melphalan can be associated with
high incidences of mixed chimerism (MC). We have previ-
ously observed a signiﬁcant effect of dose and timing of
alemtuzumab on incidences of MC in patients with HLH.
Here we sought to determine the effects of alemtuzumab
schedule and dose on chimerism in a large cohort of patients
treated with RIC.
Methods: We performed 187 RIC HCT in 186 pediatric
patients between 2004 and March, 2012. Fourteen patients
were excluded because of regimen alterations due to
illness or intolerance (n¼13) or malignancy relapse (n¼1).
All patients received ﬂudarabine 150mg/M2 (1mg/kg if
<10kg) divided over days -8 to -4 or -7 to -3, and
melphalan 140mg/M2 (4.7mg/kg if <10kg) on day -3 or -2.
RIC HCT procedures were divided into 3 groups based
upon the timing and dose of alemtuzumab. The distal
group received alemtuzumab with a dose escalation
schedule of 3mg/10mg/15mg/20mg or 3mg/10mg/10mg/
10mg starting on day -23, -22, or -21. The intermediate
group received 1mg/kg alemtuzumab divided over 5 days
starting on day -14. The proximal group received alem-
tuzumab beginning on days -12, -11, -9 or -8, with either
of the dosing schemas. The distal group was further
subdivided based on cumulative alemtuzumab doses of
greater or less than 3mg/kg (the median dose/kg). The
cumulative incidences (CI) of MC were compared.
Results: A 75% CI of MC was observed in the proximal
group, versus 32% and 39% of patients treated with the
intermediate and distal schemas (p<0.0001). Within the
distal group, the CI of MC was 67% in patients who received
>3mg/kg and 28% in patients who received <3mg/kg
(p¼0.008).
Conclusion: Proximal dosing of alemtuzumab with relation
to graft infusion and higher doses of alemtuzumab signiﬁ-
cantly increase the incidence of mixed chimerism.28
Pretargeted Radioimmunotherapy Using an Anti-CD45
Antibody-Streptavidin Conjugate and Radiolabeled
DOTA-Biotin in Patients with High-Risk Acute Leukemia
or Myelodysplastic Syndrome Undergoing Allogeneic
Hematopoietic Cell Transplantation
Raya Mawad 1,2, Ted Gooley 1, Joseph G. Rajendran 3,
Darrell R. Fisher 4, Andrew Shields 3, Johnnie J. Orozco 1,2,
Donald K. Hamlin 5, D. Scott Wilbur 5, Mark D. Hylarides 1,
Ajay K. Gopal 1,2, Damian J. Green 1,2, David G. Maloney 1,2,
Brenda M. Sandmaier 1,2, Rainer F. Storb 1,6,
Frederick R. Appelbaum1,2, Oliver W. Press 1,2, John M. Pagel 1,2.
1 Division of Clinical Research, Fred Hutchinson Cancer
Research Center, Seattle, WA; 2Department of Medicine,
University of Washington, Seattle, WA; 3Department of
Radiology, University of Washington; 4 Paciﬁc Northwest
National Laboratory, Richland, WA; 5 Radiation Oncology,
University of Washington, Seattle, WA; 6 Fred Hutchinson
Cancer Research Center
Radioimmunotherapy (RIT) has been employed to
decrease relapse after hematopoietic cell transplantation
